Clinical Trials
0
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
No trial phase data available
No trial data available
No trial data available
No approval data available
- CRISM Therapeutics reported preclinical data showing its ChemoSeed drug delivery platform achieved 72% cancer cell kill rate with sustained docetaxel administration versus 65% with intermittent dosing. - The ChemoSeed platform enables sustained drug release over at least 28 days, potentially offering improved therapeutic efficacy through local and continuous chemotherapy delivery. - The company has secured a collaborative doctoral partnership with Ulster University to advance docetaxel-ChemoSeed development for personalized prostate cancer treatment.
- Researchers at Ulster University have identified protein markers in senescent cells for earlier diagnosis and more effective treatment of Chronic Kidney Disease (CKD). - The novel method allows healthcare providers to quickly determine which CKD patients are likely to maintain stable kidney function versus those who may worsen. - Specific proteins and genetic markers associated with severe COVID-19 cases were identified, aiding in predicting patients at risk of serious symptoms or long-term effects. - Early detection of these markers could transform the management of CKD and COVID-19, potentially reducing hospital admissions and easing strain on healthcare services.
